Want to see HK:1302 full AI Analyst Report?
1302 Stock Chart & Stats
HK$1.58
HK$0.01(0.75%)
At close: 4:00 PM EST
HK$1.58
HK$0.01(0.75%)
Day’s Range― - ―
52-Week RangeHK$1.30 - HK$2.44
Previous CloseN/A
Volume6.38M
Average Volume (3M)26.58M
Market Cap
HK$6.09B
Enterprise ValueHK$5.00B
Total Cash (Recent Filing)HK$1.20B
Total Debt (Recent Filing)HK$8.04M
Price to Earnings (P/E)37.0
Beta0.91
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.79
Price to Sales (P/S)4.58
P/FCF Ratio12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.47B
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationA 50.9% YoY revenue rebound in 2025 indicates strengthening product demand and successful commercialization. Sustained top-line growth enhances scale economics, supports continued R&D and sales investment, and provides a durable driver for medium-term margin recovery if sustained.
Conservative Balance SheetVery low leverage and a sizable equity base reduce financial distress risk and preserve strategic optionality. For a medical device company with long product cycles and regulatory needs, this conservatism supports funding clinical work, geographic expansion, or M&A without pressuring liquidity.
Improved Free Cash FlowMaterial FCF improvement and near-par conversion to net income in 2025 signal meaningful cash-generation capacity. Durable cash flow strengthens internal funding for commercialization, working capital and capex, lowering reliance on external financing over the medium term.
Bears Say
Margin Compression And Low ROESteep margin decline and a weak ROE reflect deteriorating earnings power and capital efficiency versus earlier years. If driven by structural pricing pressure, cost inflation, or adverse mix, these trends can materially limit sustainable profitability and long-term shareholder returns.
Uneven Cash ConversionVolatile FCF and modest OCF-to-profit ratios indicate earnings quality variability and working-capital sensitivity. This unpredictability can constrain steady reinvestment, complicate planning for regulatory/clinical spend, and increase the chance of episodic external financing needs.
Deteriorating Profitability And Efficiency Vs Peers/earlier YearsDespite recent revenue gains, operating and net margin deterioration versus 2021–2022 suggests structural efficiency loss or cost pressures. Persistent efficiency declines undermine long-term returns and weaken competitive positioning unless management reverses cost or mix trends.
LifeTech Scientific Corporation News
1302 FAQ
What was LifeTech Scientific Corporation’s price range in the past 12 months?
LifeTech Scientific Corporation lowest stock price was HK$1.30 and its highest was HK$2.44 in the past 12 months.
What is LifeTech Scientific Corporation’s market cap?
LifeTech Scientific Corporation’s market cap is HK$6.09B.
When is LifeTech Scientific Corporation’s upcoming earnings report date?
LifeTech Scientific Corporation’s upcoming earnings report date is Aug 28, 2026 which is in 39 days.
How were LifeTech Scientific Corporation’s earnings last quarter?
LifeTech Scientific Corporation released its earnings results on Mar 31, 2026. The company reported HK$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.023.
Is LifeTech Scientific Corporation overvalued?
According to Wall Street analysts LifeTech Scientific Corporation’s price is currently Overvalued.
Does LifeTech Scientific Corporation pay dividends?
LifeTech Scientific Corporation does not currently pay dividends.
What is LifeTech Scientific Corporation’s EPS estimate?
LifeTech Scientific Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LifeTech Scientific Corporation have?
LifeTech Scientific Corporation has 4,631,712,400 shares outstanding.
What happened to LifeTech Scientific Corporation’s price movement after its last earnings report?
LifeTech Scientific Corporation reported an EPS of HK$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of LifeTech Scientific Corporation?
Currently, no hedge funds are holding shares in HK:1302
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeTech Scientific Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. The company’s products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. It also involved in the biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―